International Clinical Trial: A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07455071) titled 'A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer' on March 2.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Peking University Third Hospital

Condition: HRD-negative Epithelial Ovarian Cancer

Intervention: Biological: Tumor Neoantigen-Sensitized Autologous Dendritic Cell Injection (YS247)...